Avadel Pharmaceuticals plc [NASDAQ: AVDL] loss -4.42% on the last trading session, reaching $8.64 price per share at the time.
If compared to the average trading volume of 1.14M shares, AVDL reached a trading volume of 4049315 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Avadel Pharmaceuticals plc [AVDL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AVDL shares is $17.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AVDL stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Deutsche Bank have made an estimate for Avadel Pharmaceuticals plc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 11, 2025. While these analysts kept the previous recommendation, Rodman & Renshaw raised their target price to Buy. The new note on the price target was released on June 12, 2024, representing the official price target for Avadel Pharmaceuticals plc stock. Previously, the target price had yet another raise from $27 to $29, while Oppenheimer kept a Outperform rating on AVDL stock. On March 05, 2024, analysts increased their price target for AVDL shares from 20 to 22.
The Average True Range (ATR) for Avadel Pharmaceuticals plc is set at 0.48, with the Price to Sales ratio for AVDL stock in the period of the last 12 months amounting to 4.94. The Price to Book ratio for the last quarter was 11.29, with the Price to Cash per share for the same quarter was set at 0.76.
Trading performance analysis for AVDL stock
Avadel Pharmaceuticals plc [AVDL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.35. With this latest performance, AVDL shares gained by 27.06% in over the last four-week period, additionally sinking by -44.15% over the last 6 months – not to mention a drop of -52.79% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AVDL stock in for the last two-week period is set at 56.23, with the RSI for the last a single of trading hit 55.79, and the three-weeks RSI is set at 54.79 for Avadel Pharmaceuticals plc [AVDL]. The present Moving Average for the last 50 days of trading for this stock 8.05, while it was recorded at 8.77 for the last single week of trading, and 11.25 for the last 200 days.
Avadel Pharmaceuticals plc [AVDL]: A deeper dive into fundamental analysis
Avadel Pharmaceuticals plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.33 and a Current Ratio set at 2.75.
An analysis of Institutional ownership at Avadel Pharmaceuticals plc [AVDL]
The top three institutional holders of AVDL stocks are: JANUS HENDERSON GROUP PLC with ownership of 13.3 million shares, which is approximately 13.8296%. POLAR CAPITAL HOLDINGS PLC, holding 6.56 million shares of the stock with an approximate value of $$92.24 million in AVDL stocks shares; and POLAR CAPITAL HOLDINGS PLC, currently with $$80.71 million in AVDL stock with ownership which is approximately 5.9699%.
